Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic risk reduction related to metabolic dysfunction-associated steatotic liver disease (MASLD). Baseline and follow-up (minimum 12 weeks) clinical, anthropometric, and laboratory data from 154 patients treated at a single tertiary-care center in Turkey were analyzed. The study assessed whether short-term incretin-based therapy was associated with changes in fibrosis-related indices (FIB-4, APRI) versus steatosis- and insulin resistance-related indices (HSI, TyG), and identified independent predictors of these changes using multivariable linear regression.

NCT Number	NCT07701005
Lead Sponsor	Goztepe Prof Dr Suleyman Yalcın City Hospital
Conditions	Steatosis of Liver, Metabolic Liver Injury, Obesity, Overweight, Insulin Resistance
Enrollment	154 participants
Start Date	2024-01-01
Primary Completion	2026-03-30 (estimated)
Study Completion	2026-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-15